Virtual/JJ
Screening/JJ
for/IN
Potential/JJ
Inhibitors/NNS
of/IN
NS3/NN
Protein/NN
of/IN
Zika/NN
Virus/NN
./.
====================
Zika/DT
virus/NN
(/(
ZIKV/NN
)/)
is/VBZ
a/DT
mosquito/JJ
borne/NN
pathogen/NN
,/,
belongs/VBZ
to/TO
Flaviviridae/NN
family/NN
having/VBG
a/DT
positive-sense/JJ
single-stranded/JJ
RNA/NN
genome/NN
,/,
currently/RB
known/VBN
for/IN
causing/VBG
large/JJ
epidemics/NNS
in/IN
Brazil/NN
./.
====================
Its/PRP$
infection/NN
can/MD
cause/VB
microcephaly/RB
,/,
a/DT
serious/JJ
birth/NN
defect/NN
during/IN
pregnancy/NN
./.
====================
The/DT
recent/JJ
outbreak/JJ
of/IN
ZIKV/NN
in/IN
February/JJ
2016/CD
in/IN
Brazil/NN
realized/VBD
it/PRP
as/IN
a/DT
major/JJ
health/NN
risk/NN
,/,
demands/VBZ
an/DT
enhanced/VBN
surveillance/NN
and/CC
a/DT
need/JJ
to/TO
develop/VB
novel/JJ
drugs/NNS
against/IN
ZIKV/NN
./.
====================
Amodiaquine/IN
,/,
prochlorperazine/NN
,/,
quinacrine/RB
,/,
and/CC
berberine/NN
are/VBP
few/JJ
promising/VBG
drugs/NNS
approved/JJ
by/IN
Food/NN
and/CC
Drug/NN
Administration/NN
against/IN
dengue/JJ
virus/NN
which/WDT
also/RB
belong/IN
to/TO
Flaviviridae/NN
family/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
performed/VBD
molecular/JJ
docking/NN
analysis/NN
of/IN
these/DT
drugs/NNS
against/IN
nonstructural/JJ
3/CD
(/(
NS3/NN
)/)
protein/NN
of/IN
ZIKV/NN
./.
====================
The/DT
protease/NN
activity/NN
of/IN
NS3/NN
is/VBZ
necessary/JJ
for/IN
viral/JJ
replication/NN
and/CC
its/PRP$
prohibition/NN
could/MD
be/VB
considered/VBN
as/IN
a/DT
strategy/NN
for/IN
treatment/NN
of/IN
ZIKV/NN
infection/NN
./.
====================
Amongst/IN
these/DT
four/CD
drugs/NNS
,/,
berberine/NN
has/VBZ
shown/VBN
highest/JJS
binding/VBG
affinity/NN
of/IN
–5.8/CD
kcal/mol/NN
and/CC
it/PRP
is/VBZ
binding/VBG
around/IN
the/DT
active/JJ
site/NN
region/NN
of/IN
the/DT
receptor/NN
./.
====================
Based/VBN
on/IN
the/DT
properties/NNS
of/IN
berberine/JJ
,/,
more/RBR
similar/JJ
compounds/NNS
were/VBD
retrieved/VBN
from/IN
ZINC/NN
database/NN
and/CC
a/DT
structure-based/JJ
virtual/JJ
screening/NN
was/VBD
carried/VBN
out/RP
by/IN
AutoDock/NN
Vina/NN
in/IN
PyRx/NN
0.8/CD
./.
====================
Best/RB
10/CD
novel/JJ
drug-like/JJ
compounds/NNS
were/VBD
identified/VBN
and/CC
amongst/IN
them/PRP
ZINC53047591/NN
(/(
2-/CD
(/(
benzylsulfanyl/JJ
)/)
-3-cyclohexyl-3H-spiro/RB
[/(
benzo/IN
[/(
h/NN
]/)
quinazoline-5,1'-cyclopentan/RB
]/)
-4/CD
(/(
6H/NN
)/)
-one/NN
)/)
was/VBD
found/VBN
to/TO
interact/VB
with/IN
NS3/NN
protein/NN
with/IN
binding/VBG
energy/NN
of/IN
–7.1/NN
kcal/mol/NN
and/CC
formed/VBD
H-bonds/NNS
with/IN
Ser135/NN
and/CC
Asn152/NN
amino/NN
acid/NN
residues/NNS
./.
====================
Observations/NNS
made/VBD
in/IN
this/DT
study/NN
may/MD
extend/VB
an/DT
assuring/VBG
platform/NN
for/IN
developing/VBG
anti-viral/JJ
competitive/JJ
inhibitors/NNS
against/IN
ZIKV/NN
infection/NN
./.
====================
Zika/NN
virus/NN
(/(
ZIKV/NN
)/)
,/,
belongs/VBZ
to/TO
family/NN
``/CD
Flaviviradae/NN
''/CD
having/VBG
genus/NN
``/CD
Flavivirus/NN
''/CD
[/(
1/CD
]/)
,/,
is/VBZ
a/DT
mosquito-borne/JJ
flavivirus/NN
./.
====================
It/PRP
transmits/VBZ
mainly/RB
through/IN
vectors/NNS
from/IN
the/DT
Aedes/NNS
genus/NN
and/CC
monkeys/NNS
[/(
2/CD
]/)
./.
====================
Humans/NNS
get/NN
infected/JJ
by/IN
infected/JJ
mosquito/NN
bites/VBZ
or/CC
by/IN
direct/JJ
contact/NN
probably/RB
during/IN
sexual/JJ
intercourse/JJ
[/(
3/CD
]/)
./.
====================
Symptoms/NNS
associated/VBN
with/IN
the/DT
viral/JJ
infection/NN
are/VBP
fever/NN
,/,
mild/JJ
headache/NN
,/,
malaise/JJ
,/,
conjunctivitis/NN
,/,
rashes/VBZ
,/,
and/CC
arthralgia/NN
./.
====================
The/DT
illness/NN
by/IN
ZIKV/NN
is/VBZ
usually/RB
not/RB
much/RB
severe/JJ
and/CC
there/EX
is/VBZ
a/DT
long-term/JJ
symptoms/NNS
for/IN
more/RBR
than/IN
a/DT
few/JJ
days/NNS
to/TO
a/DT
week/NN
after/IN
infected/JJ
by/IN
mosquito/JJ
./.
====================
As/IN
the/DT
mortality/NN
rate/NN
of/IN
ZIKV/NN
infection/NN
is/VBZ
very/RB
rare/JJ
with/IN
less/RBR
severe/JJ
sickness/JJ
,/,
many/JJ
people/JJ
might/MD
not/RB
realize/VB
they/PRP
have/VBP
been/VBN
infected/VBN
./.
====================
There/EX
is/VBZ
an/DT
augmented/JJ
risk/NN
of/IN
microcephaly/RB
development/NN
along/IN
with/IN
severe/JJ
fetal/JJ
brain/NN
defects/NNS
in/IN
the/DT
fetus/NN
of/IN
pregnant/JJ
women/NNS
when/WRB
she/PRP
infected/JJ
with/IN
ZIKV/NN
[/(
4/CD
]/)
./.
====================
In/IN
1947/CD
,/,
the/DT
ZIKV/NN
was/VBD
first/JJ
isolated/VBN
from/IN
the/DT
blood/NN
of/IN
a/DT
sentinel/NN
rhesus/NN
monkey/NN
number/NN
766/CD
living/JJ
in/IN
Zika/NN
forest/VBP
at/IN
Uganda/NN
[/(
2/CD
]/)
./.
====================
In/IN
2007/CD
,/,
ZIKV/NN
spreads/VBZ
from/IN
Africa/JJ
and/CC
Asia/NN
to/TO
cause/VB
the/DT
largest/JJS
outbreak/JJ
in/IN
humans/NNS
on/IN
Pacific/JJ
island/NN
of/IN
Yap/NN
[/(
5/CD
]/)
./.
====================
There/EX
are/VBP
around/IN
73/CD
%/NN
of/IN
yep/NN
residents/NNS
over/IN
the/DT
age/NN
of/IN
3/CD
years/NNS
were/VBD
infected/VBN
with/IN
ZIKV/NN
whereas/IN
no/DT
deaths/NNS
were/VBD
subjected/VBN
[/(
56/CD
]/)
./.
====================
The/DT
viral/JJ
illness/NN
become/VBP
apparent/JJ
disease/NN
due/JJ
to/TO
the/DT
increasing/VBG
distribution/NN
area/NN
of/IN
ZIKV/NN
,/,
confirming/VBG
by/IN
the/DT
recent/JJ
epidemic/JJ
French/JJ
Polynesia/NN
,/,
new/JJ
Caledonian/JJ
since/IN
October/NN
2013/CD
[/(
7/CD
]/)
and/CC
crook/JJ
island/NN
in/IN
March/JJ
2014/CD
./.
====================
In/IN
May/NN
2015/CD
,/,
the/DT
Pan/NN
American/NN
Health/NN
Organization/NN
and/CC
World/NN
Health/NN
Organization/NN
(/(
WHO/NN
)/)
issued/VBD
an/DT
epidemiological/JJ
alert/NN
to/TO
ZIKV/NN
infection/NN
[/(
8/CD
]/)
./.
====================
Brazilian/JJ
health/NN
officials/VBZ
confirm/VBP
a/DT
case/NN
of/IN
ZIKV/NN
infection/NN
transmitted/VBD
by/IN
transfused/VBN
blood/NN
from/IN
an/DT
infected/JJ
donor/NN
in/IN
February/JJ
2016/CD
./.
====================
There/EX
are/VBP
two/CD
types/NNS
of/IN
diagnosis/NN
for/IN
ZIKV/NN
are/VBP
available/JJ
,/,
one/CD
is/VBZ
the/DT
detection/NN
of/IN
the/DT
virus/NN
and/CC
viral/JJ
components/NNS
through/IN
reverse/JJ
transcription/NN
polymerase/NN
chain/NN
reaction/NN
,/,
immunoassay/NN
and/CC
virus/NN
isolation/NN
and/CC
the/DT
other/JJ
one/CD
is/VBZ
based/VBN
on/IN
the/DT
antibody/NN
detection/NN
extracted/VBN
by/IN
ZIKV/NN
infection/NN
[/(
6/CD
]/)
./.
====================
A/DT
preliminary/JJ
diagnosis/NN
is/VBZ
also/RB
carried/VBD
out/RP
based/VBN
on/IN
patients/NNS
clinical/JJ
features/NNS
,/,
place/NN
and/CC
date/NN
of/IN
travel/JJ
and/CC
activities/NNS
./.
====================
Laboratory/JJ
diagnosis/NN
is/VBZ
generally/RB
able/JJ
by/IN
testing/VBG
serum/NN
or/CC
plasma/NN
to/TO
detect/VB
virus/NN
./.
====================
ZIKV/NN
consist/VBP
of/IN
a/DT
single/JJ
stranded/JJ
,/,
positive/JJ
sense/NN
,/,
5'-capped/JJ
RNA/NN
with/IN
genome/NN
size/NN
of/IN
around/IN
11/CD
kb/NN
which/WDT
immediately/RB
released/VBN
into/IN
the/DT
cytoplasm/NN
following/VBG
by/IN
cell/NN
entry/NN
[/(
9/CD
]/)
./.
====================
There/EX
are/VBP
59/CD
and/CC
39/CD
un-translated/JJ
regions/NNS
along/IN
with/IN
only/RB
one/CD
open/JJ
reading/NN
frame/NN
which/WDT
codes/VBZ
a/DT
polyprotein/JJ
that/IN
further/RB
cleaved/VBN
into/IN
three/CD
structural/JJ
proteins/NNS
i.e./FW
,/,
the/DT
capsid/NN
(/(
c/LS
)/)
,/,
envelope/NN
(/(
E/NN
)/)
and/CC
premembrane/membrane/JJ
(/(
prM/NN
)/)
;/:
and/CC
seven/CD
nonstructural/JJ
(/(
NS/NNS
)/)
proteins/NNS
i.e./FW
,/,
NS1/NN
,/,
NS2A/NN
,/,
NS2B/NN
,/,
NS3/NN
,/,
NS4A/NNP
,/,
NS4B/NN
,/,
and/CC
NS5/NN
[/(
10/CD
]/)
./.
====================
Among/IN
them/PRP
the/DT
NS3/NN
and/CC
NS5/NN
proteins/NNS
play/VBP
a/DT
central/JJ
role/NN
,/,
together/RB
they/PRP
harbor/VBP
most/JJS
of/IN
the/DT
catalytic/JJ
activities/NNS
needed/VBN
for/IN
capping/VBG
and/CC
replication/NN
[/(
9/CD
]/)
./.
====================
The/DT
NS5/NN
consist/VBP
of/IN
an/DT
N-terminal/JJ
methyl-transferase/NN
(/(
NS5/NN
MTase/NN
)/)
domain/NN
,/,
c-terminal/JJ
RNA/NN
dependent/JJ
,/,
RNA/NN
polymerase/NN
(/(
NS5/NN
RdRp/NN
)/)
./.
====================
Whereas/IN
NS3/NN
is/VBZ
a/DT
multi-domain/JJ
protein/NN
with/IN
an/DT
N-terminal/JJ
NS3pro/NN
and/CC
c-terminal/JJ
fraction/NN
containing/VBG
the/DT
RNA/NN
triphosphatase/NN
(/(
NS3/NN
RTpase/NN
)/)
and/CC
RNA/NN
helicase/NN
(/(
NS3/NN
hel/NN
)/)
activities/NNS
involves/VBZ
in/IN
viral/JJ
RNA/NN
synthesis/NN
[/(
111213/CD
]/)
./.
====================
The/DT
375/CD
kDa/NN
flaviviral/JJ
polyprotein/NN
precursor/NN
is/VBZ
processed/VBN
by/IN
host/NN
proteases/NNS
and/CC
a/DT
virus/NN
encoded/VBN
protease/NN
activity/NN
localized/VBD
at/IN
the/DT
N-terminal/JJ
domain/NN
of/IN
NS3/NN
./.
====================
Whereas/IN
at/IN
the/DT
junctions/NNS
prM-E/NN
,/,
C-prM/JJ
,/,
NS4A-NS4B/NN
,/,
E-NS1/NN
[/(
1415/CD
]/)
,/,
and/CC
likely/RB
also/RB
NS1-NS2A/NN
[/(
16/CD
]/)
,/,
is/VBZ
carried/VBN
out/RP
by/IN
the/DT
host/NN
signal/NN
peptidase/NN
located/JJ
within/IN
the/DT
lumen/NNS
of/IN
endoplasmic/JJ
reticulum/NN
,/,
the/DT
left/NN
over/IN
peptide/NN
bonds/NNS
between/IN
NS2B-NS3/NN
,/,
NS2A-NS2B/NN
,/,
NS3-NS4A/NN
,/,
and/CC
NS4B-NS5/NN
are/VBP
cleaved/VBN
by/IN
NS3Pro/NN
./.
====================
Cleavage/NN
at/IN
the/DT
NS2B/NS3/NN
site/NN
is/VBZ
carried/VBN
out/RP
in/IN
cis/NN
but/CC
is/VBZ
not/RB
essential/JJ
for/IN
protease/NN
activity/NN
[/(
1718/CD
]/)
./.
====================
Thus/RB
,/,
the/DT
protease/NN
activity/NN
of/IN
NS3/NN
protein/NN
is/VBZ
very/RB
essential/JJ
for/IN
viral/JJ
replication/NN
and/CC
its/PRP$
inhibition/NN
has/VBZ
to/TO
be/VB
evaluated/VBN
as/IN
a/DT
valuable/JJ
approach/NN
for/IN
treatment/NN
against/IN
flaviviral/JJ
infections/NNS
[/(
9/CD
]/)
./.
====================
Thus/RB
,/,
the/DT
NS3/NN
protein/NN
may/MD
be/VB
considered/VBN
as/IN
important/JJ
drug/NN
target/NN
./.
====================
Currently/RB
,/,
there/EX
is/VBZ
no/DT
medicines/NNS
and/CC
vaccines/NNS
developed/VBD
against/IN
ZIKV/NN
or/CC
specific/JJ
antiviral/JJ
treatment/NN
for/IN
clinical/JJ
ZIKV/NN
infection/NN
./.
====================
Treatment/NN
is/VBZ
normally/RB
supportive/JJ
and/CC
can/MD
include/VB
rest/VBP
,/,
intake/JJ
of/IN
fluids/NNS
,/,
and/CC
use/NN
of/IN
antipyretics/NNS
and/CC
analgesics/NNS
[/(
19/CD
]/)
./.
====================
There/EX
are/VBP
some/DT
Food/JJ
and/CC
Drug/NN
Administration/NN
(/(
FDA/NN
)/)
approved/JJ
drugs/NNS
such/JJ
as/IN
:/:
amodiaquine/IN
[/(
20/CD
]/)
,/,
prochlorperazine/JJ
[/(
21/CD
]/)
,/,
quinacrine/RB
,/,
and/CC
berberine/JJ
[/(
22/CD
]/)
,/,
were/VBD
reported/VBN
to/TO
be/VB
effective/JJ
(/(
in/IN
vitro/FW
or/CC
in/IN
vivo/FW
)/)
against/IN
dengue/JJ
virus/NN
(/(
DENV/NN
)/)
which/WDT
is/VBZ
also/RB
a/DT
Flavivirus/NN
./.
====================
There/EX
are/VBP
many/JJ
things/NNS
that/DT
dengue/VBP
and/CC
Zika/NN
have/VBP
in/IN
common/JJ
like/IN
they/PRP
both/CC
are/VBP
mosquito/RBS
borne/NN
viruses/NNS
spread/VBN
especially/RB
by/IN
the/DT
Aedes/NNS
mosquito/JJS
./.
====================
Both/DT
have/VBP
similar/JJ
symptoms/NNS
./.
====================
The/DT
difference/NN
is/VBZ
that/DT
ZIKV/NN
symptoms/NNS
last/JJ
for/IN
few/JJ
days/NNS
or/CC
weeks/NNS
and/CC
then/RB
they/PRP
subside/VBP
but/CC
for/IN
dengue/JJ
the/DT
fever/NN
last/JJ
for/IN
weeks/NNS
and/CC
that/IN
can/MD
further/RBR
lead/VBP
to/TO
bruising/VBG
and/CC
bleeding/VBG
./.
====================
Both/DT
dengue/NN
and/CC
Zika/NN
have/VBP
three/CD
structural/JJ
proteins/NNS
and/CC
seven/CD
nonstructural/JJ
./.
====================
Quinacrine/NN
is/VBZ
also/RB
active/JJ
against/IN
Ebola/NN
virus/NN
[/(
23/CD
]/)
./.
====================
As/IN
ZIKV/NN
also/RB
belong/VBP
to/TO
the/DT
Flaviviradae/NN
family/NN
,/,
these/DT
drugs/NNS
may/MD
have/VB
some/DT
therapeutic/JJ
effect/NN
against/IN
ZIKV/NN
./.
====================
Thus/RB
in/IN
this/DT
study/NN
,/,
we/PRP
have/VBP
taken/VBN
these/DT
four/CD
FDA/NN
approved/JJ
drugs/NNS
against/IN
DENV/NN
as/IN
ligands/NNS
and/CC
performed/VBN
molecular/JJ
docking/NN
analysis/NN
against/IN
NS3/NN
protein/NN
of/IN
ZIKV/NN
in/IN
order/NN
to/TO
observe/VB
the/DT
binding/NN
affinity/NN
of/IN
these/DT
drugs/NNS
./.
====================
Among/IN
these/DT
four/CD
drugs/NNS
,/,
the/DT
drug/NN
showing/VBG
minimum/JJ
binding/NN
energy/NN
has/VBZ
been/VBN
considered/VBN
as/IN
the/DT
lead/NN
drug/NN
for/IN
further/JJ
analysis/NN
./.
====================
Further/RB
,/,
drug/NN
like/IN
compounds/NNS
with/IN
similar/JJ
physiochemical/JJ
properties/NNS
of/IN
the/DT
lead/NN
drug/NN
,/,
have/VBP
been/VBN
retrieved/VBN
from/IN
ZINC/NN
database/NN
for/IN
virtual/JJ
screening/NN
against/IN
NS3/NN
protein/NN
,/,
in/IN
order/NN
to/TO
identify/VB
novel/JJ
drugs/NNS
for/IN
ZIKV/NN
./.
====================
Hardware/JJ
and/CC
software/JJ
====================
The/DT
study/NN
was/VBD
carried/VBN
out/RP
on/IN
Dell/NN
Workstation/NN
with/IN
2.26/CD
GHz/NN
processor/NN
,/,
6/CD
GB/NN
RAM/NN
and/CC
500/CD
GB/NN
hard/VBP
drive/VBP
running/JJ
in/IN
Windows/NNS
operating/VBG
system/NN
./.
====================
Bioinformatics/NNS
software/RB
,/,
such/JJ
as/IN
PyRx/JJ
0.8/CD
[/(
24/CD
]/)
,/,
Phyre2/NN
[/(
25/CD
]/)
,/,
AutoDock/NN
Vina/NNP
[/(
26/CD
]/)
and/CC
online/RB
resources/VBZ
like/IN
NCBI/NN
[/(
27/CD
]/)
,/,
ProCheck/NNP
at/IN
RCSB/NN
validation/NN
server/RB
[/(
28/CD
]/)
,/,
ProSA-web/NNP
[/(
29/CD
]/)
,/,
ZINC/NN
database/NN
(/(
https/NNS
:/:
//zinc.docking.org/JJ
)/)
,/,
ProQ/NNP
[/(
30/CD
]/)
,/,
ERRAT/NN
server/RB
[/(
31/CD
]/)
,/,
etc/JJ
./.
====================
were/VBD
used/VBN
in/IN
this/DT
study/NN
./.
====================
Protein/NN
structure/NN
prediction/NN
and/CC
validation/NN
of/IN
drug/NN
target/NN
====================
The/DT
sequence/NN
of/IN
NS3/NN
protein/NN
(/(
accession/NN
No/DT
./.
====================
YP_009227202/NN
)/)
of/IN
ZIKV/NN
was/VBD
retrieved/VBN
from/IN
NCBI/NN
database/NN
[/(
27/CD
]/)
./.
====================
Phyre2/NN
servers/NNS
predict/VBP
the/DT
three-dimensional/JJ
(/(
3D/NN
)/)
structure/NN
of/IN
a/DT
protein/NN
sequence/NN
using/VBG
the/DT
principles/NNS
and/CC
techniques/NNS
of/IN
homology/NN
modeling/VBG
./.
====================
Because/IN
the/DT
structure/NN
of/IN
a/DT
protein/NN
is/VBZ
more/RBR
conserved/VBN
in/IN
evolution/NN
than/IN
its/PRP$
amino/NN
acid/NN
sequence/NN
,/,
a/DT
protein/NN
sequence/NN
of/IN
interest/JJ
(/(
the/DT
target/NN
)/)
can/MD
be/VB
modeled/VBN
with/IN
reasonable/JJ
accuracy/NN
on/IN
a/DT
very/RB
distantly/RB
related/JJ
sequence/NN
of/IN
known/JJ
structure/NN
(/(
the/DT
template/JJ
)/)
,/,
provided/VBD
that/DT
the/DT
relationship/NN
between/IN
target/NN
and/CC
template/JJ
can/MD
be/VB
discerned/VBN
through/IN
sequence/NN
alignment/NN
./.
====================
Phyre2/NN
was/VBD
used/VBN
for/IN
modelling/VBG
the/DT
3D/NN
structure/NN
of/IN
NS3/NN
protein/NN
,/,
it/PRP
is/VBZ
a/DT
suite/JJ
of/IN
tools/NNS
available/JJ
on/IN
the/DT
web/NN
to/TO
predict/VB
and/CC
analyze/VB
protein/NN
structure/NN
,/,
function/NN
and/CC
mutations/NNS
./.
====================
The/DT
focus/NN
of/IN
Phyre2/NN
is/VBZ
to/TO
provide/VB
biologists/NNS
with/IN
a/DT
simple/JJ
and/CC
intuitive/JJ
interface/NN
to/TO
state-of-the-art/VB
protein/NN
bioinformatics/NNS
tools/NNS
[/(
29/CD
]/)
./.
====================
The/DT
refined/VBN
model/NN
reliability/NN
was/VBD
assessed/VBN
through/IN
,/,
ProSA-web/NNP
,/,
the/DT
ProSA/NN
program/NN
(/(
Protein/NN
Structure/NN
Analysis/NN
)/)
is/VBZ
an/DT
established/JJ
tool/NN
which/WDT
has/VBZ
a/DT
large/JJ
user/NN
base/NN
and/CC
is/VBZ
frequently/RB
employed/VBN
in/IN
the/DT
refinement/JJ
and/CC
validation/NN
of/IN
experimental/JJ
protein/NN
structures/NNS
[/(
29/CD
]/)
,/,
and/CC
ProQ/NN
is/VBZ
a/DT
neural/JJ
network/NN
based/VBN
predictor/NN
that/IN
based/VBN
on/IN
a/DT
number/NN
of/IN
structural/JJ
features/NNS
predicts/VBZ
the/DT
quality/NN
of/IN
a/DT
protein/NN
model/NN
[/(
30/CD
]/)
./.
====================
Further/RB
the/DT
refined/VBN
model/NN
was/VBD
verified/VBN
by/IN
ERRAT/NN
server/RB
,/,
ERRAT/NN
is/VBZ
a/DT
program/NN
for/IN
verifying/VBG
protein/NN
structures/NNS
determined/VBN
by/IN
crystallography/NN
./.
====================
Error/NN
values/NNS
are/VBP
plotted/VBN
as/IN
a/DT
function/NN
of/IN
the/DT
position/NN
of/IN
a/DT
sliding/JJ
9-residue/JJ
window/NN
./.
====================
The/DT
error/JJ
function/NN
is/VBZ
based/VBN
on/IN
the/DT
statistics/NNS
of/IN
non-bonded/JJ
atom-atom/IN
interactions/NNS
in/IN
the/DT
reported/VBN
structure/NN
[/(
31/CD
]/)
./.
====================
Ligand/NN
preparation/NN
and/CC
molecular/JJ
docking/NN
====================
Chemical/JJ
structures/NNS
of/IN
ligands/NNS
(/(
amodiaquine/NN
,/,
prochlorperazine/NN
,/,
quinacrine/RB
,/,
and/CC
berberine/NN
)/)
used/VBN
in/IN
this/DT
study/NN
were/VBD
retrieved/VBN
from/IN
the/DT
PubChem/JJ
database/NN
[/(
32/CD
]/)
./.
====================
PDBQT/NN
files/NNS
of/IN
ligands/NNS
and/CC
receptor/NN
molecules/NNS
(/(
NS3/NN
)/)
was/VBD
prepared/VBN
./.
====================
Then/RB
the/DT
protein-ligand/NN
docking/NN
studies/NNS
were/VBD
performed/VBN
using/VBG
the/DT
AutoDock/NN
Vina/NN
program/NN
[/(
26/CD
]/)
./.
====================
It/PRP
is/VBZ
one/CD
of/IN
the/DT
widely/RB
use/NN
method/NN
for/IN
protein-ligand/NN
docking/NN
./.
====================
AutoDock/NN
Vina/NN
significantly/RB
improves/VBZ
the/DT
average/NN
accuracy/NN
of/IN
the/DT
binding/NN
mode/NN
predictions/NNS
./.
====================
For/IN
the/DT
input/NN
and/CC
output/NN
,/,
Vina/NN
uses/VBZ
the/DT
PDBQT/NN
molecular/JJ
structure/NN
file/JJ
format/IN
./.
====================
Here/RB
PDBQT/NN
file/JJ
of/IN
four/CD
drugs/NNS
were/VBD
taken/VBN
as/IN
ligand/NN
and/CC
PDBQT/NN
file/JJ
of/IN
NS3/NN
was/VBD
taken/VBN
as/IN
protein/NN
./.
====================
These/DT
drug/NN
compounds/NNS
were/VBD
docked/VBN
with/IN
NS3/NN
protein/NN
of/IN
ZIKV/NN
and/CC
NS3/NN
protein/NN
of/IN
DENV/NN
around/IN
its/PRP$
important/JJ
binding/NN
site/NN
residues/NNS
such/JJ
as/IN
His51/NN
,/,
Asp75/NN
,/,
and/CC
Ser135/NN
./.
====================
Virtual/JJ
screening/NN
====================
Virtual/JJ
screening/NN
is/VBZ
now/RB
well-known/JJ
as/IN
an/DT
efficient/JJ
prototype/NN
for/IN
filtering/VBG
compounds/NNS
for/IN
drug/NN
discovery/NN
./.
====================
It/PRP
was/VBD
carried/VBN
out/RP
using/VBG
PyRx/JJ
0.8/CD
(/(
Virtual/JJ
Screening/JJ
Tools/NNS
)/)
./.
====================
All/DT
the/DT
drug-like/JJ
compounds/NNS
retrieved/VBD
from/IN
ZINC/NN
database/NN
in/IN
SDF/NN
format/IN
in/IN
a/DT
single/JJ
file/JJ
./.
====================
The/DT
SDF/NN
file/JJ
was/VBD
imported/VBN
in/IN
open/JJ
babel/NN
of/IN
PyRx/NN
and/CC
further/RBR
energy/NN
minimization/NN
of/IN
all/DT
the/DT
ligands/NNS
were/VBD
performed/VBN
followed/VBN
by/IN
conversion/NN
of/IN
all/DT
the/DT
ligands/NNS
into/IN
AutoDock/NN
PDBQT/NN
format/IN
./.
====================
Further/RB
,/,
these/DT
ligands/NNS
were/VBD
subjected/VBN
to/TO
docking/NN
against/IN
NS3/NN
protein/NN
of/IN
ZIKV/NN
using/VBG
AutoDock/NN
Vina/NN
in/IN
PyRx/NN
0.8/CD
[/(
26/CD
]/)
./.
====================
The/DT
NS3/NN
protein/NN
(/(
accession/NN
No/DT
./.
====================
YP_009227202/NN
)/)
of/IN
ZIKV/NN
has/VBZ
617/CD
amino/NN
acids/NNS
residues/NNS
and/CC
NS3/NN
protein/NN
of/IN
DENV/NN
(/(
accession/NN
No/DT
./.
====================
NP_740321.1/NN
)/)
has/VBZ
618/CD
amino/NN
acid/NN
residues/NNS
in/IN
its/PRP$
protein/NN
sequence/NN
./.
====================
The/DT
NS3/NN
protein/NN
of/IN
both/DT
ZIKV/NNP
and/CC
DENV/NN
have/VBP
structurally/RB
similar/JJ
with/IN
three/CD
conserve/JJ
domain/NN
,/,
i.e./FW
,/,
FLAVIVIRUS_NS3PRO/NN
,/,
Flavivirus/NN
NS3/NN
protease/NN
(/(
NS3pro/NNP
)/)
domain/NN
;/:
HELICASE_ATP_BIND_1/NN
,/,
superfamilies/VBZ
1/CD
and/CC
2/CD
helicase/NN
ATP-binding/VBG
type-1/NN
domain/NN
;/:
and/CC
HELICASE_CTER/NN
,/,
superfamilies/VBZ
1/CD
and/CC
2/CD
helicase/NN
C-terminal/JJ
domain/NN
(/(
predicted/VBN
from/IN
ScanProsite/JJ
tool/NN
of/IN
ExPASy/JJ
)/)
[/(
33/CD
]/)
;/:
however/RB
,/,
there/EX
are/VBP
67/CD
%/NN
identities/VBZ
and/CC
100/CD
%/NN
similarities/NNS
in/IN
their/PRP$
amino/NN
acid/NN
sequences/NNS
obtained/VBN
from/IN
BLASTP/NN
result/NN
[/(
34/CD
]/)
./.
====================
Protein/NN
structure/NN
modeling/VBG
and/CC
validation/NN
====================
Three-dimensional/JJ
structure/NN
of/IN
both/DT
NS3/NN
proteins/NNS
(/(
Fig/NN
./.
====================
1A/NN
)/)
were/VBD
modeled/VBN
using/VBG
Phyre2/NN
server/RB
which/WDT
has/VBZ
taken/VBN
chain/NN
A/DT
of/IN
2VBC/NN
(/(
crystal/JJ
structure/NN
of/IN
the/DT
NS3/NN
protease-helicase/NN
from/IN
DENV/NN
)/)
as/IN
template/JJ
for/IN
modeling/VBG
having/VBG
100/CD
%/NN
confidence/NN
and/CC
67/CD
%/NN
identity/NN
./.
====================
From/IN
the/DT
ProCheck/NN
analysis/NN
obtained/VBN
from/IN
Ramachandran/NN
plot/NN
(/(
Fig/NN
./.
====================
1B/NN
)/)
,/,
it/PRP
was/VBD
observed/VBN
that/IN
88.8/CD
%/NN
residues/NNS
were/VBD
located/JJ
in/IN
most/JJS
favorable/JJ
region/NN
,/,
9.8/CD
%/NN
were/VBD
in/IN
additional/JJ
allowed/VBD
region/NN
,/,
0.4/CD
%/NN
residues/NNS
in/IN
generously/RB
allowed/VBD
regions/NNS
whereas/IN
0.9/CD
%/NN
of/IN
the/DT
residues/NNS
located/JJ
in/IN
disallowed/JJ
region/NN
./.
====================
The/DT
compatible/JJ
Z/NN
score/NN
value/NN
of/IN
–10.71/CD
(/(
Fig/NN
./.
====================
1C/NN
)/)
obtained/VBN
from/IN
ProSA-web/NN
evaluation/NN
revealed/VBD
that/IN
the/DT
modelled/JJ
structure/NN
is/VBZ
fit/JJ
within/IN
the/DT
range/NN
of/IN
native/JJ
conformation/NN
of/IN
crystal/JJ
structures/NNS
[/(
29/CD
]/)
./.
====================
Further/RB
,/,
the/DT
overall/JJ
residue/NN
energies/VBZ
of/IN
NS3/NN
was/VBD
largely/RB
negative/JJ
(/(
Fig/NN
./.
====================
1D/CD
)/)
./.
====================
The/DT
modelled/JJ
NS3/NN
protein/NN
of/IN
ZIKV/NN
showed/VBD
Levitt-Gerstein/NN
(/(
LG/NN
)/)
score/RB
of/IN
5.060/CD
by/IN
Protein/NN
Quality/NN
Predictor/NN
(/(
ProQ/NN
)/)
tool/NN
,/,
it/PRP
implies/VBZ
the/DT
high/JJ
accuracy/NN
level/NN
of/IN
the/DT
predicted/VBN
structure/NN
and/CC
taken/VBN
to/TO
account/VB
as/IN
extremely/RB
good/JJ
model/NN
./.
====================
The/DT
ProQ/NN
LG/NN
score/RB
of/IN
more/RBR
than/IN
2.5/CD
is/VBZ
needed/VBN
to/TO
proposing/VBG
a/DT
predicted/VBN
structure/NN
is/VBZ
of/IN
very/RB
good/JJ
quality/NN
[/(
30/CD
]/)
./.
====================
By/IN
using/VBG
ERRAT/JJ
plot/NN
same/JJ
assumptions/NNS
were/VBD
achieved/VBN
,/,
where/WRB
the/DT
overall/JJ
quality/NN
factor/NN
is/VBZ
67.002/CD
%/NN
./.
====================
All/DT
of/IN
the/DT
above/JJ
out/RP
comes/NNS
recommended/VBN
the/DT
reliability/NN
of/IN
the/DT
proposed/JJ
model/NN
./.
====================
Protein-ligand/CC
docking/NN
====================
Different/JJ
studies/NNS
have/VBP
already/RB
reported/VBN
that/IN
the/DT
nonstructural/JJ
NS3/NN
protein/NN
is/VBZ
very/RB
essential/JJ
for/IN
the/DT
development/NN
of/IN
the/DT
viral/JJ
polyprotein/NN
and/CC
is/VBZ
a/DT
suitable/JJ
target/NN
for/IN
designing/VBG
antiviral/JJ
inhibitors/NNS
[/(
32/CD
]/)
./.
====================
Analysis/NN
of/IN
the/DT
amino/NN
acid/NN
sequence/NN
of/IN
the/DT
NS3/NN
protein/NN
of/IN
hepatitis/NN
C/NN
virus/NN
suggested/VBD
that/IN
this/DT
viral/JJ
protein/NN
contains/VBZ
a/DT
trypsin-like/JJ
serine/NN
protease/NN
domain/NN
that/DT
functions/VBZ
in/IN
the/DT
processing/NN
of/IN
the/DT
viral/JJ
polyprotein/NN
[/(
35/CD
]/)
./.
====================
NS3/NN
protein/NN
of/IN
ZIKV/NN
contains/VBZ
catalytic/JJ
triad/NN
of/IN
His51/NN
,/,
Asp75/NN
,/,
and/CC
Ser135/NN
[/(
9/CD
]/)
./.
====================
The/DT
active/JJ
site/NN
of/IN
serine/NN
proteases/NNS
in/IN
variably/RB
contains/VBZ
three/CD
residues/NNS
,/,
histidine/NN
,/,
aspartate/NN
,/,
and/CC
serine/NN
that/DT
maintain/VBP
the/DT
same/JJ
relative/JJ
spatial/JJ
position/NN
in/IN
all/DT
the/DT
known/JJ
structures/NNS
of/IN
these/DT
enzymes/NNS
./.
====================
Thus/RB
,/,
we/PRP
performed/VBD
molecular/JJ
docking/NN
of/IN
four/CD
FDA/NN
approved/JJ
drugs/NNS
using/VBG
AutoDock/NN
Vina/NN
[/(
26/CD
]/)
around/IN
the/DT
active/JJ
site/NN
residues/NNS
of/IN
NS3/NN
protein/NN
of/IN
both/DT
ZIKV/NN
and/CC
DENV/NN
./.
====================
From/IN
the/DT
docking/NN
analysis/NN
,/,
it/PRP
was/VBD
observed/VBN
that/IN
among/IN
all/DT
the/DT
drugs/NNS
berberine/VBP
showed/VBD
the/DT
lowest/JJS
binding/VBG
energy/NN
in/IN
both/DT
ZIKV/NN
and/CC
DENV/NN
of/IN
–5.8/CD
kcal/mol/NN
and/CC
–6.6/CD
kcal/mol/NN
respectively/RB
./.
====================
In/IN
ZIKV/NN
,/,
berberine/NN
has/VBZ
formed/VBN
hydrogen/NN
bond/NN
with/IN
Ser135/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Likewise/RB
other/JJ
three/CD
drugs/NNS
,/,
i.e./FW
,/,
amodiaquine/NN
,/,
prochlorperazine/NN
,/,
and/CC
Quinacrine/NN
also/RB
docked/VBD
with/IN
NS3/NN
protein/NN
of/IN
both/DT
ZIKV/NN
and/CC
DENV/NN
with/IN
considerable/JJ
binding/NN
energy/NN
(/(
Table/JJ
1/CD
)/)
./.
====================
From/IN
ZIKV/NN
protein-ligand/CC
docking/NN
we/PRP
select/VBP
the/DT
ligand/NN
having/VBG
lowest/JJS
binding/NN
energy/NN
then/RB
proceed/VBD
for/IN
screening/NN
to/TO
get/VB
more/RBR
similar/JJ
drug/NN
like/IN
compounds/NNS
./.
====================
Virtual/JJ
screening/NN
and/CC
validation/NN
of/IN
docking/NN
results/NNS
====================
The/DT
virtual/JJ
screening/NN
technique/NN
is/VBZ
an/DT
economical/JJ
,/,
reliable/JJ
and/CC
time/NN
saving/JJ
method/NN
for/IN
screening/NN
large/JJ
set/NN
of/IN
lead/NN
molecules/NNS
./.
====================
In/IN
our/PRP$
study/NN
,/,
we/PRP
have/VBP
used/VBN
PyRx/NN
0.8/CD
[/(
24/CD
]/)
for/IN
screening/NN
lead/VBP
molecules/NNS
against/IN
NS3/NN
protein/NN
was/VBD
used/VBN
to/TO
solve/VB
the/DT
purpose/NN
./.
====================
The/DT
NS3/NN
protein/NN
of/IN
ZIKV/NN
was/VBD
used/VBN
as/IN
receptor/NN
to/TO
screen/VB
4,121/CD
drug-like/JJ
compounds/NNS
(/(
small/JJ
molecules/NNS
)/)
based/VBN
on/IN
properties/NNS
of/IN
berberine/JJ
such/JJ
as/IN
molecular/JJ
weight/NN
of/IN
336.367/CD
g/mol/NN
,/,
Xlog/NN
p-value/JJ
of/IN
0.20/CD
,/,
net/RB
charge/JJ
of/IN
1/CD
,/,
rotatable/JJ
bonds/NNS
2/CD
,/,
polar/JJ
surface/NN
area/NN
41Å2/CD
,/,
hydrogen/NN
donor/NN
0/CD
,/,
hydrogen/NN
acceptor/NN
5/CD
,/,
apolar/JJ
desolvation/NN
8.91/CD
kcal/mol/NN
,/,
and/CC
polar/JJ
desolvation/NN
of/IN
8.91/CD
kcal/mol/NN
./.
====================
Further/RB
,/,
an/DT
approximate/JJ
range/NN
molecular/JJ
weight/NN
ranges/VBZ
from/IN
(/(
300/CD
to/TO
400/CD
g/mol/NN
)/)
;/:
Xlog/NNP
p/NN
(/(
0.10/CD
to/TO
0.50/CD
)/)
;/:
net/RB
charge/JJ
(/(
–1/LS
to/TO
3/CD
)/)
;/:
rotatable/JJ
bonds/VBZ
(/(
1/LS
to/TO
5/CD
)/)
;/:
polar/JJ
surface/NN
area/NN
(/(
20/CD
to/TO
60/CD
Å2/NN
)/)
;/:
hydrogen/NN
donor/NN
(/(
0/CD
to/TO
5/CD
)/)
;/:
hydrogen/NN
acceptor/IN
(/(
2/CD
to/TO
8/CD
)/)
;/:
apolar/JJ
desolvation/NN
(/(
5/CD
to/TO
15/CD
kcal/mol/NN
)/)
;/:
and/CC
polar/JJ
desolvation/NN
ranges/VBZ
from/IN
(/(
–40/CD
to/TO
–10/CD
kcal/mol/NN
)/)
was/VBD
taken/VBN
to/TO
retrieve/JJ
similar/JJ
drug/NN
compounds/NNS
from/IN
ZINC/NN
database/NN
./.
====================
AutoDock/NN
Vina/NN
[/(
26/CD
]/)
in/IN
PyRx/NN
0.8/CD
was/VBD
employed/VBN
for/IN
screening/NN
the/DT
ligands/NNS
which/WDT
generates/VBZ
nine/CD
distinct/JJ
poses/VBZ
of/IN
each/DT
ligand/NN
./.
====================
Further/RB
,/,
based/VBN
on/IN
the/DT
hydrogen/NN
bond/NN
interaction/NN
with/IN
active/JJ
site/NN
residues/NNS
of/IN
NS3/NN
,/,
the/DT
docking/NN
pose/VBP
for/IN
each/DT
ligand/NN
was/VBD
selected/VBN
./.
====================
Top/RB
ten/CD
drug/NN
like/IN
compounds/NNS
(/(
Table/JJ
2/CD
)/)
obtained/VBN
by/IN
virtual/JJ
screening/NN
bound/VBD
to/TO
catalytic/JJ
site/NN
of/IN
NS3/NN
protein/NN
with/IN
lowest/JJS
binding/VBG
energy/NN
were/VBD
taken/VBN
as/IN
promising/JJ
candidates/NNS
for/IN
further/JJ
analysis/NN
./.
====================
All/DT
the/DT
ligand/NN
molecules/NNS
observed/VBN
to/TO
follow/VB
the/DT
Lipinski/NN
's/POS
rule/JJ
of/IN
five/CD
(/(
molecular/JJ
weight/NN
not/RB
more/RBR
than/IN
500/CD
Da/NN
;/:
hydrogen/NN
bond/NN
donor/NN
not/RB
more/RBR
than/IN
5/CD
;/:
hydrogen/NN
bond/NN
acceptors/NNS
not/RB
more/RBR
than/IN
10/CD
;/:
log/NN
p-value/JJ
not/RB
greater/JJR
than/IN
5/CD
)/)
./.
====================
The/DT
chemical/JJ
structure/NN
of/IN
these/DT
ten/CD
compounds/NNS
along/IN
with/IN
known/VBN
inhibitor/NN
berberine/NN
are/VBP
given/VBN
in/IN
Fig/NN
./.
====================
3/CD
./.
====================
All/DT
the/DT
proposed/JJ
lead/VBP
molecules/NNS
were/VBD
observed/VBN
to/TO
form/VB
hydrogen/NN
bonds/NNS
with/IN
active/JJ
site/NN
residues/NNS
of/IN
NS3/NN
protein/NN
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
The/DT
Lead/JJ
1/CD
molecule/NN
is/VBZ
ZINC53047591/NN
(/(
2/CD
(/(
benzylsulfanyl/JJ
)/)
-3-cyclohexyl-3H-spiro/RB
[/(
benzo/IN
[/(
h/NN
]/)
quinazoline-5,1'-cyclopent/RB
an/DT
]/)
-4/CD
(/(
6H/NN
)/)
-one/NN
)/)
;/:
having/VBG
molecular/JJ
weight/NN
456.64218/CD
(/(
g/mol/NN
)/)
showed/VBD
the/DT
lowest/JJ
binding/VBG
of/IN
–7.1/NN
kcal/mol/NN
and/CC
observed/VBN
to/TO
interact/VB
with/IN
active/JJ
site/NN
residues/NNS
of/IN
NS3/NN
by/IN
forming/VBG
hydrogen/NN
bonds/NNS
with/IN
SER135/NN
and/CC
ASN152/NN
./.
====================
The/DT
other/JJ
nine/CD
lead/VBP
molecules/NNS
are/VBP
also/RB
observed/VBN
to/TO
inhibit/VB
NS3/NN
protein/NN
with/IN
significant/JJ
lower/JJR
binding/NN
energy/NN
as/IN
compared/VBN
to/TO
berberine/VB
./.
====================
Thus/RB
,/,
the/DT
higher/JJR
binding/NN
affinity/NN
of/IN
selected/VBN
lead/VBP
molecules/NNS
compared/VBN
to/TO
berberine/VB
in/IN
respective/JJ
docking/NN
complexes/NNS
proposed/VBN
that/IN
the/DT
selected/VBN
ligands/NNS
would/MD
probably/RB
bind/VBP
more/RBR
competitively/RB
in/IN
the/DT
active/JJ
site/NN
of/IN
NS3/NN
protein/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
participation/NN
of/IN
selected/VBN
lead/VBP
molecules/NNS
have/VBP
very/RB
important/JJ
role/NN
to/TO
inhibit/VB
the/DT
NS3/NN
protein/NN
through/IN
hydrogen/NN
bonding/VBG
interaction/NN
with/IN
its/PRP$
active/JJ
site/NN
residues/NNS
justified/VBN
them/PRP
as/IN
possible/JJ
inhibitors/NNS
against/IN
the/DT
important/JJ
enzyme/NN
of/IN
ZIKV/NN
./.
====================
Therefore/RB
,/,
the/DT
given/VBN
inhibitors/NNS
may/MD
be/VB
demonstrated/VBN
through/IN
biochemical/JJ
assays/NNS
./.
====================
In/IN
conclusion/NN
,/,
the/DT
ZIKV/NN
belongs/VBZ
to/TO
Flaviviridae/NN
family/NN
,/,
which/WDT
is/VBZ
similar/JJ
to/TO
DENV/NN
,/,
West/NNP
Nile/JJ
virus/NN
and/CC
yellow/IN
fever/NN
virus/NN
./.
====================
Currently/RB
,/,
there/EX
are/VBP
no/DT
specific/JJ
drugs/NNS
for/IN
prevention/NN
and/CC
treatment/NN
of/IN
ZIKV/NN
./.
====================
As/IN
,/,
the/DT
NS3/NN
protein/NN
of/IN
this/DT
virus/NN
perform/VBP
a/DT
central/JJ
part/NN
in/IN
the/DT
viral/JJ
life/NN
cycle/NN
,/,
it/PRP
is/VBZ
of/IN
appreciable/JJ
interest/NN
in/IN
designing/VBG
new/JJ
potential/JJ
drug/NN
candidate/NN
to/TO
deal/JJ
with/IN
conquer/NN
the/DT
challenges/NNS
of/IN
ZIKV/NN
infection/NN
./.
====================
A/DT
high/JJ
quality/NN
3D/NN
structure/NN
of/IN
NS3/NN
protein/NN
was/VBD
predicted/VBN
and/CC
validated/VBD
through/IN
computational/JJ
approach/NN
and/CC
molecular/JJ
docking/NN
technique/NN
was/VBD
employed/VBN
to/TO
observe/VB
the/DT
interaction/NN
of/IN
the/DT
existing/VBG
drugs/NNS
used/VBN
against/IN
other/JJ
flavivirus/NN
,/,
against/IN
ZIKV/NN
NS3/NN
protein/NN
./.
====================
Further/RB
,/,
for/IN
identifying/VBG
novel/JJ
inhibitors/NNS
,/,
high-throughput/JJ
virtual/JJ
screening/NN
approach/NN
was/VBD
employed/VBN
in/IN
this/DT
study/NN
,/,
would/MD
be/VB
of/IN
significant/JJ
in/IN
designing/VBG
new/JJ
drugs/NNS
for/IN
ZIKV/NN
infection/NN
./.
====================
(/(
A/NN
)/)
Three-dimensional/JJ
structure/NN
of/IN
predicted/VBN
nonstructural/JJ
3/CD
(/(
NS3/NN
)/)
protein/NN
model/NN
of/IN
Zika/NN
virus/NN
(/(
ZIKV/NN
)/)
./.
====================
(/(
B/NN
)/)
Ramachandran/NN
plot/NN
of/IN
predicted/VBN
NS3/NN
model/NN
./.
====================
(/(
C/NN
)/)
ProSA-web/NN
Z-scores/NNS
of/IN
all/DT
protein/NN
chains/NNS
in/IN
Protein/NN
Data/NNS
Bank/NN
determined/VBN
by/IN
X-ray/NN
crystallography/NN
and/CC
nuclear/JJ
magnetic/JJ
resonance/NN
spectroscopy/NN
with/IN
respect/NN
to/TO
their/PRP$
length/NN
./.
====================
The/DT
Z-score/JJ
of/IN
NS3/NN
was/VBD
present/JJ
in/IN
that/DT
range/NN
represented/VBN
in/IN
dot/JJ
./.
====================
(/(
D/NN
)/)
Energy/NN
plot/NN
for/IN
the/DT
predicted/VBN
NS3/NN
protein/NN
of/IN
ZIKV/NN
./.
====================
(/(
E/NN
)/)
ERRAT/NN
plot/NN
for/IN
residue-wise/JJ
analysis/NN
of/IN
homology/NN
model/NN
./.
====================
aOn/IN
the/DT
error/NN
axis/NN
,/,
two/CD
lines/NNS
are/VBP
drawn/VBN
to/TO
indicate/VB
the/DT
confidence/NN
with/IN
which/WDT
it/PRP
is/VBZ
possible/JJ
to/TO
reject/VB
regions/NNS
that/IN
exceed/VBP
that/DT
error/VBP
value/NN
./.
====================
Molecular/JJ
docking/NN
complex/NN
of/IN
berberine/JJ
with/IN
nonstructural/JJ
3/CD
(/(
NS3/NN
)/)
protein/NN
of/IN
Zika/NN
virus/NN
./.
====================
Chemical/JJ
structure/NN
of/IN
10/CD
best/IN
lead/VBP
molecules/NNS
:/:
ZINC53047591/CD
(/(
A/DT
)/)
,/,
ZINC13510840/NN
(/(
B/NN
)/)
,/,
ZINC19705600/NN
(/(
C/NN
)/)
,/,
ZINC19711173/NN
(/(
D/NN
)/)
,/,
ZINC25634061/NN
(/(
E/NN
)/)
,/,
ZINC98342354/NN
(/(
F/NN
)/)
,/,
ZINC02974658/NN
(/(
G/NN
)/)
,/,
ZINC04086851/NN
(/(
H/NN
)/)
,/,
ZINC98342344/NN
(/(
I/NN
)/)
,/,
ZINC02974656/NN
(/(
J/NNP
)/)
,/,
and/CC
known/VBN
inhibitor/NN
berberine/NN
:/:
ZINC03779067/CD
(/(
K/NN
)/)
./.
====================
Docking/VBG
interaction/NN
structure/NN
of/IN
10/CD
best/IN
lead/VBP
molecules/NNS
and/CC
known/VBN
inhibitor/NN
berberine/NN
along/IN
with/IN
hydrogen/NN
bonds/NNS
:/:
ZINC53047591/CD
(/(
A/DT
)/)
,/,
ZINC13510840/NNP
(/(
B/NN
)/)
,/,
ZINC19705600/NN
(/(
C/NN
)/)
,/,
ZINC19711173/NNP
(/(
D/NN
)/)
,/,
ZINC25634061/NN
(/(
E/NNP
)/)
,/,
ZINC98342354/NN
(/(
F/NN
)/)
,/,
ZINC02974658/NN
(/(
G/NN
)/)
,/,
ZINC04086851/NNP
(/(
H/NN
)/)
,/,
ZINC98342344/NN
(/(
I/NN
)/)
,/,
ZINC02974656/NN
(/(
J/NNP
)/)
,/,
and/CC
berberine/IN
:/:
ZINC03779067/CD
(/(
K/NN
)/)
./.
====================
Docking/VBG
result/NN
of/IN
four/CD
Food/JJ
and/CC
Drug/NN
Administration/NN
approved/JJ
drugs/NNS
against/IN
NS3/NN
protein/NN
of/IN
ZIKV/NN
and/CC
DENV/NN
====================
Docking/VBG
result/NN
of/IN
ten/CD
best/JJS
lead/VBP
molecules/NNS
against/IN
NS3/NN
protein/NN
of/IN
Zika/NN
virus/NN
along/IN
with/IN
berberine/JJ
====================
